---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-077598"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2023-07-03T23:59:59+00:00"
generated_at: "2026-06-13T13:05:05.363149+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics CAO departs; appoints Eliot Lurier as Interim CFO

## Summary
- Michael Loiacono, Chief Accounting Officer, separated effective June 30, 2023.
- Company agreed to provide severance benefits consistent with employment agreement upon execution of release.
- Eliot M. Lurier appointed Interim CFO effective June 30; serves via Danforth Advisors consulting agreement.
- Mr. Lurier, age 65, has served as consultant to life science companies through Danforth since July 2021.
- No family relationships or material transactions between Lurier and company officers/directors.

## SEC filing metadata
- accession: 0001104659-23-077598
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2023-07-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465923077598/0001104659-23-077598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465923077598/tm2319618d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-077598
- JSON: https://secwatch.observer/filing/0001104659-23-077598.json
- Plain text: https://secwatch.observer/filing/0001104659-23-077598.txt

## Key facts
- Executive change
  Michael Loiacono departed as Chief Accounting Officer at Marker Therapeutics, Inc..
  - Action: separated
  - Role: Chief Accounting Officer
  source text: Michael Loiacono, the Chief Accounting Officer of Marker Therapeutics, Inc. (the “ Company ”), was separated from the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465923077598/0001104659-23-077598-index.htm
- Executive change
  Eliot M. Lurier was appointed as Interim Chief Financial Officer at Marker Therapeutics, Inc..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: the Company appointed Eliot M. Lurier as the Company’s Interim Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465923077598/0001104659-23-077598-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.